Research Funded

Identifying mechanisms of osteosarcoma chemoresistance that arise from the lung metastatic niche

Ryan Roberts, MD, PhD, The Research Institute at Nationwide Children’s Hospital
Recipient of the: $50,000 Pittsburgh Cure Sarcoma Research Award

Abstract: A therapy preventing the emergence of lung metastasis in adolescents with osteosarcoma could save more than 70% of the lives currently lost to this disease. This would represent the most significant improvement in outcome ... Read More

Imaging response to CD47 mAb immunotherapy in pediatric patients with osteosarcoma

Heike Daldrup-Link, MD, PhD, Stanford University
Recipient of the: $50,000 Race to Cure Sarcoma Research Award

Abstract: Children with metastatic bone cancer have a poor prognosis, with an overall survival rate of less than 30%. Stanford investigators developed a new drug, monoclonal antibodies against the cancer cell marker CD47 (CD mAb), w... Read More

The Role of Pseudogenes as Regulators of the IGF2BP2/IGF1R/RAS Axis in Rhabdomyosarcoma: Functional Characterization in Myogenesis and Implications for Anticancer Therapy

Sonia Guil, PhD, Josep Carreras Leukaemia Research Institute
Recipient of the: $50,000 Race to Cure Sarcoma Research Award

Abstract: In the study of cellular mechanisms that are out of control in cancer, noncoding RNAs(ncRNAs) are becoming increasingly important: these are transcripts that do not code for proteins, but which frequently play regulatory r... Read More

Phase I-II trial of sunitinib plus nivolumab after standard treatment in advanced soft tissue and bone sarcomas

Javier Martin-Broto, MD, PhD, Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla
Recipient of the: $50,000 Race to Cure Sarcoma Research Award

Abstract: Sarcomas are rare, life-threatening, malignant tumors affecting soft, visceral, and bone tissues. Due to their high heterogeneity (more than 60 subtypes), many sarcomas lack effective therapies. Incidence is 50-60 new case... Read More

Immunomodulation of Ewing sarcoma to enhance allogenic NK cell therapy

Masanori Hayashi, MD, University of Colorado Denver
Recipient of the: $50,000 Sarcoma Foundation of America Research Award

Abstract: While the introduction of the combination of intensive chemotherapy and multi-modal While the use of chemotherapy, surgery and irradiation have improved outcomes in Ewing sarcoma (ES), such about 70% of patients are cure, ... Read More

Dissecting DNA damage and repair pathways in leiomyosarcomas: Improving therapy by understanding biology

Annette Duensing, MD, University of Pittsburgh Cancer Institute
Recipient of the: $50,000 Dr. Richard and Valerie Aronsohn Memorial Research Award

Abstract: Leiomyosarcomas (LMS) are aggressive tumors of the smooth muscle with no available effective treatments and a 2-year survival rate of 20%. They represent up to 25% of all soft tissue sarcomas (STS) and are the most common ... Read More

Single-cell transcriptomics and epigenomics to identify tumor-microenvironment Interactions for targeted treatment of MPNST

Lai Man Natalie Wu, PhD, Cincinnati Children’s Hospital Medical Center
Recipient of the: $50,000 Zach Cohen Memorial Research Award

Abstract: MPNST (malignant peripheral nerve sheath tumors) are highly aggressive soft tissue sarcomas of Schwann cell (SC) origin, representing a major cause of mortality in neurofibromatosis (NF) patients, which affects 1 in 3500 i... Read More

Intratumoral heterogeneity in dedifferentiated liposarcoma

Joshua Waterfall, PhD, Institut Curie (France)
Recipient of the: $50,000 Jay Vernon Jackson Memorial Research Award

Abstract: Soft tissue sarcomas are a rare entity of very heterogeneous tumors, both epidemiological, histological and molecular. Clinically, sarcomas can occur at any age of life and develop throughout the body. They are associated ... Read More

Resetting the epigenetic addiction in leiomyosarcomas: a therapeutic perspective

Claudio Brancolini, PhD, University of Udine (Italy)
Recipient of the: $50,000 Spring for Sarcoma York, PA, Sarcoma Research Award

Abstract: Leiomyosarcomas (LMS) are rare highly malignant tumors of mesenchymal origin. Standard treatment is surgery and adjuvant radiotherapy. Unfortunately, local recurrence and metastasis develop in approximately 40% of cases, w... Read More

Switching the tumor immune microenvironment from “cold” to “hot” in UPS

Jlenia Guarnerio, PhD, Cedars-Sinai Medical Center
Recipient of the: $50,000 Spring for Sarcoma York, PA, Sarcoma Research Award

Abstract: Undifferentiated Pleiomorphic Sarcoma (UPS) is one of the most aggressive subtypes of soft tissue sarcoma. Besides earlier detection by novel imaging techniques, little has been found to improve the overall survival of the... Read More

Immune profiling of pleomorphic rhabdomyosarcoma

Andrew Futreal, PhD, MD Anderson Cancer Center
Recipient of the: $50,000 Race to Cure Sarcoma Research Award

Abstract: Pleomorphic rhabdomyosarcoma (PRMS) is a rare soft tissue tumor of the skeletal muscle that occurs predominantly in middle-aged adults. No standard systemic therapy options are available, and surgical resection is the most... Read More

Characterizing the Genetic Landscape of Radiation Associated Cutaneous Angiosarcomas

David Shultz, MD, PhD, Princess Margaret Cancer Centre (Canada)
Recipient of the: $50,000 Race to Cure Sarcoma Research Award

Abstract: Radiation-associated cutaneous angiosarcoma (RAA) is a highly aggressive malignancy that arises in breast cancer patients approximately 5-10 years following treatment with adjuvant radiotherapy (RT). The median survival of... Read More